KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ginkgo Bioworks Holdings (DNA) Payables: 2020-2025

Historic Payables for Ginkgo Bioworks Holdings (DNA) over the last 5 years, with Sep 2025 value amounting to $10.7 million.

  • Ginkgo Bioworks Holdings' Payables fell 31.82% to $10.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $47.3 million, marking a year-over-year decrease of 36.92%. This contributed to the annual value of $14.2 million for FY2024, which is 51.98% up from last year.
  • According to the latest figures from Q3 2025, Ginkgo Bioworks Holdings' Payables is $10.7 million, which was down 4.45% from $11.2 million recorded in Q2 2025.
  • In the past 5 years, Ginkgo Bioworks Holdings' Payables registered a high of $35.3 million during Q1 2022, and its lowest value of $1.4 million during Q1 2021.
  • Moreover, its 3-year median value for Payables was $13.6 million (2023), whereas its average is $15.3 million.
  • As far as peak fluctuations go, Ginkgo Bioworks Holdings' Payables soared by 2,379.71% in 2022, and later tumbled by 58.26% in 2025.
  • Over the past 5 years, Ginkgo Bioworks Holdings' Payables (Quarterly) stood at $8.2 million in 2021, then increased by 27.62% to $10.5 million in 2022, then fell by 10.79% to $9.3 million in 2023, then spiked by 51.98% to $14.2 million in 2024, then plummeted by 31.82% to $10.7 million in 2025.
  • Its Payables stands at $10.7 million for Q3 2025, versus $11.2 million for Q2 2025 and $11.3 million for Q1 2025.